住院精神分裂症患者利培酮、氯氮平治疗的成本效益比较  

Study of cost-effectiveness on risperidone vs clozapine in the treatment of inpatients with schizophrenia.

作　　者：毛叶萌[1] 笪志民[1] 

机构地区：[1]上海市精神卫生中心,200030

出　　处：《上海精神医学》2000年第4期211-213,共3页Shanghai Archives of Psychiatry

摘　　要：目的 比较利培酮和氯氮平治疗住院精神分裂症病人的疗效和费用。方法 利培酮组30例(男性16例,女性14例,平均年龄26.8岁),氯氮平组26例(男性12例,女性14例,平均年龄30.6岁),BPRS评分>30分。比较两组病人住院期间的所有治疗费用及出院时疗效。结果 利培酮组与氯氮平组疗效相当,氯氮平组除住院期间主药费用小于利培酮,其他费用均高于利培酮。结论 利培酮与氯氮平疗效相当,住院总费用小于氯氮平,是一种安全且经济有效的抗精神病药物。Objectives: To compare therapeutic effects and costs between risperidone and clozapine in the treatment of schizophrenia during hospitalization. Method: Thirty patients with schizophrenia received risperidone treatment, and twenty-six patients received clozapine treatment. The therapeutic effects and total costs were evaluated and compared. Results: The response rates of this two drugs were similar, the major durg costs in risperidone group were higher than those of clozapine and the total costs in risperidone group were lower than those of clozapine. Conclusion: The results suggests that risperidone is a favorably cost-effective antipsychotic agent.

关 键 词：利培酮 氯氮平 成本效益 精神分裂症 治疗 

分 类 号：R749.3[医药卫生—神经病学与精神病学]